Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06949033RecruitingPhase 3
Cadonilimab with chemo for stomach cancer
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
Lanzhou, GansuAges 18–75 - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75 - NCT06954077RecruitingPhase 1
BL-M09D1 for advanced gastrointestinal and other solid tumors
This trial tests a new drug, BL-M09D1, for people with advanced or metastatic gastrointestinal or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06956001RecruitingPhase 3
Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06961357RecruitingPhase 1/Phase 2
CD40L-Enhanced TIL therapy for advanced melanoma
This trial tests a new way to treat advanced melanoma by taking immune cells from your tumor, enhancing them in the lab to fight better, and giving them back to you. It is for people whose melanoma has spread or cannot be removed, and who have already tried standard treatments.
Tampa, FloridaAges 18 years+ - NCT07008287Recruiting
Taletrectinib for ROS1+ lung cancer with brain spread
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Hangzhou, ZhejiangAges 18 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07016724RecruitingPhase 2
Study of radiation and chemo with cadonilizumab for esophageal cancer
This trial tests combining radiation, chemotherapy, and the drug cadonilizumab before surgery for locally advanced esophageal squamous cell cancer. It aims to shrink the tumor and improve treatment outcomes.
Zhengzhou, HenanAges 18–75 - NCT07016997RecruitingPhase 1
A study of CBA-1535 for advanced solid tumors
This trial tests a new drug, CBA-1535, which is designed to help your immune system attack cancer cells. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
Nagaizumicho, ShizuokaAges 20 years+ - NCT07018570RecruitingPhase 2
Chemo, immunotherapy, and radiation for stomach cancer before surgery
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Kashiwa, ChibaAges 18 years+ - NCT07024680Recruiting
Sunitinib or sorafenib for papillary kidney cancer
This study looks at how well sunitinib or sorafenib work as a first treatment for a type of kidney cancer called papillary renal cell carcinoma (PRCC) that cannot be removed with surgery or has spread. It aims to understand real-world results in Chinese patients.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07035249RecruitingPhase 1/Phase 2
DCSZ11 plus standard therapy for advanced solid tumors
This trial tests a new drug called DCSZ11 combined with usual chemotherapy and immunotherapy for people with advanced or metastatic solid tumors. It aims to see if adding DCSZ11 works better than standard treatments alone.
Chengdu, SichuanAges 18 years+ - NCT07037680RecruitingPhase 2
Radiation plus Anlotinib for advanced lung cancer
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07039162RecruitingPhase 2
Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Kaohsiung CityAges 20 years+ - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT07053072RecruitingPhase 1
PD-1 mRNA vaccine for advanced liver cancer
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
Chengdu, SichuanAges 18–70 - NCT07061704RecruitingPhase 1/Phase 2
Oncolytic virus trial for esophageal cancer
This trial tests a virus-based therapy for locally advanced esophageal squamous cell carcinoma. It aims to see if the virus can target and kill cancer cells while sparing healthy tissue.
Chengdu, SichuanAges 18–80 - NCT07066982RecruitingPhase 1/Phase 2
CAR T cells targeting CD146 and HER2 for advanced sarcomas
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07075120RecruitingPhase 1
Immunotherapy and radiation for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
Honolulu, HawaiiAges 18 years+ - NCT07085572RecruitingPhase 2
Cemiplimab for maintenance in adrenocortical cancer
This trial tests a drug called cemiplimab as a maintenance treatment for patients with adrenocortical cancer whose disease did not worsen after initial chemotherapy. It is designed to keep the cancer from coming back.
Brescia, BresciaAges 18 years+ - NCT07086300Recruiting
Acupuncture with immunotherapy for older lung cancer patients
This trial tests whether adding electroacupuncture (a gentle, needle-based therapy) to a standard immunotherapy drug (PD-1 inhibitor) can help older adults with advanced lung cancer. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 65–100 - NCT07108270RecruitingPhase 2
Study of dostarlimab plus chemotherapy for advanced or recurrent endometrial cancer
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
Jinan, ShandongAges 18 years+ - NCT07117890RecruitingPhase 2
Sunvozertinib for untreated NSCLC with EGFR rare mutations
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
ShanghaiAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,211 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.